Loading...
14 bamlanivimab/etesevimab COVID-19 controlled studies, 5 RCTs
69% improvement
for early treatment, RR
0.31
[0.16-0.60]
https://c19ly.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gottlieb (RCT)
71%
0.29 [0.09-0.96]
hosp./ER
4/101
7/52
Improvement, RR [CI]
Treatment
Control
Gottlieb (RCT)
80%
0.20 [0.03-1.56]
hosp./ER
1/37
7/52
Gottlieb (RCT)
75%
0.25 [0.03-1.92]
hosp./ER
1/30
7/52
Gottlieb (RCT)
56%
0.44 [0.10-1.98]
hosp./ER
2/34
7/52
Gottlieb (RCT)
92%
0.08 [0.00-1.39]
hosp./ER
0/31
7/52
Webb
80%
0.20 [0.03-1.46]
death
1/479
57/5,536
Webb
53%
0.47 [0.31-0.72]
hosp.
22/479
538/5,536
Webb
27%
0.73 [0.65-0.82]
hosp./ER
65/479
1,018/5,536
Dougan (DB RCT)
95%
0.05 [0.00-0.90]
death
0/518
9/517
Dougan (DB RCT)
70%
0.30 [0.16-0.59]
death/hosp.
11/518
36/517
Dougan (DB RCT)
11%
0.89 [0.82-0.97]
recov. time
518 (n)
517 (n)
Dougan (DB RCT)
67%
0.33 [0.25-0.45]
viral+
50/508
147/499
Cooper
45%
0.55 [0.07-3.99]
death
1/473
33/8,534
Cooper
58%
0.42 [0.10-1.72]
ICU
2/473
85/8,534
Cooper
5%
0.95 [0.69-1.30]
hosp.
37/473
703/8,534
Cooper
-17%
1.17 [0.59-2.32]
death
11/2,427
33/8,534
Cooper
9%
0.91 [0.57-1.45]
ICU
22/2,427
85/8,534
Cooper
28%
0.72 [0.61-0.86]
hosp.
144/2,427
703/8,534
Rubin
44%
0.56 [0.07-4.33]
death
1/191
10/1,066
Rubin
65%
0.35 [0.12-0.94]
hosp.
16/191
121/1,065
Delasobera
-119%
2.19 [0.23-20.9]
death
3/253
1/185
Delasobera
52%
0.48 [0.27-0.85]
hosp.
17/253
26/185
Delasobera
20%
0.80 [0.46-1.40]
progression
23/253
21/185
Dale
89%
0.11 [0.02-0.55]
death
5/56
9/19
Dale
86%
0.14 [0.04-0.52]
progression
6/56
10/19
Dale
54%
0.46 [0.08-1.97]
progression
6/56
3/19
Wilden
51%
0.49 [0.23-1.04]
hosp.
n/a
n/a
ACTIV-3/T.. (RCT)
-100%
2.00 [0.69-5.83]
death
9/163
5/151
Bariola
67%
0.33 [0.10-1.01]
death
4/234
12/234
Bariola
64%
0.36 [0.20-0.61]
death/hosp.
16/234
45/234
Bariola
61%
0.39 [0.22-0.70]
hosp.
15/234
39/234
Ganesh
74%
0.26 [0.05-1.20]
death
2/1,789
8/1,832
Ganesh
49%
0.51 [0.24-1.09]
ICU
10/1,789
20/1,832
Ganesh
37%
0.63 [0.43-0.91]
hosp.
44/1,789
72/1,832
Chew (RCT)
25%
0.75 [0.26-2.10]
hosp.
6/159
8/158
Chew (RCT)
52%
0.48 [0.09-2.49]
hosp.
2/48
4/46
Chew (RCT)
-1%
1.01 [0.26-3.93]
hosp.
4/111
4/112
Chew (RCT)
-14%
1.14 [0.00-455]
recov. time
48 (n)
46 (n)
Chew (RCT)
-17%
1.17 [0.98-1.40]
recov. time
111 (n)
112 (n)
Chew (RCT)
26%
0.74 [0.62-0.90]
viral load
48 (n)
46 (n)
Chew (RCT)
35%
0.65 [0.40-1.04]
viral load
111 (n)
112 (n)
Priest (PSM)
0%
1.00 [0.33-3.07]
death
6/379
6/379
Priest (PSM)
-4%
1.04 [0.78-1.38]
hosp.
79/379
76/379
Priest (PSM)
-5%
1.05 [0.73-1.52]
hosp./ER
379 (n)
379 (n)
Lilly (RCT)
57%
0.43 [0.28-0.67]
symp. case
483 (n)
482 (n)
Lilly (RCT)
80%
0.20 [0.08-0.47]
symp. case
150 (n)
149 (n)
bamlanivimab/etesevimab COVID-19 outcomes
c19ly.com Jun 2022
Favors bamlanivimab/e..
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit